Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05822999
Other study ID # WCTP-I-B-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 15, 2021
Est. completion date June 8, 2022

Study information

Verified date March 2023
Source WELT corp
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study was to determine safety and efficacy of WELT-IP in adult insomnia patients. WELT-IP is a cognitive behavioral therapy for insomnia (CBT-I) based digital therapeutics.


Description:

This was a randomized, double-blinded, sham-controlled trial. Overall, 52 subjects were randomized into the following groups: - WELT-IP group: WELT-IP (insomnia digital therapeutics) use - Control group: sham app use Subjects in both groups continued to receive their clinician-directed standard-of-care treatment for insomnia, if applicable, including pharmacotherapy. Subjects were randomized and in WELT-IP group used WELT-IP and subjects in control group used a sham for a period of 6 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date June 8, 2022
Est. primary completion date April 26, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 65 Years
Eligibility Inclusion Criteria: - DSM-5 insomnia patient - ISI of 8 or above - for 7 days before baseline visit (Visit 2), completing sleep diary for more than 4 days in the guidelines - capable of using mobile device and application Exclusion Criteria: - currently on non-pharmacological treatment for insomnia (ex. CBT-I, light therapy, oriental therapy for insomnia) - sleep disorders diagnosis other than insomnia (ex. Obstructive sleep apnea, sleep behavior problem, restless leg syndrome) - progressive and active medical conditions - received continuous psychotherapy such as CBT, motivational enhancement therapy, psychotherapy, and psychoanalysis in the past 3 months - major psychiatric illness as assessed through MINI - suicide risk as assessed through C-SSRS - having occupational risk due to sleep restriction - shift workers

Study Design


Related Conditions & MeSH terms

  • Insomnia
  • Sleep Initiation and Maintenance Disorders

Intervention

Device:
WELT-IP
WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
Sham
Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.

Locations

Country Name City State
Korea, Republic of Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
WELT corp

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other App Satisfaction Survey (for WELT-IP group only) 8 weeks
Other Sleep Environment Survey 8 weeks
Other Activity data from mobile device Activity data is evaluated as change of number of steps from baseline to week 8. 8 weeks
Other EuroQol 5 dimensions 5 level (EQ-5D-5L) Survey EuroQol 5 dimensions 5 level comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. 8 weeks
Other EuroQol-visual analogue scales (EQ-VAS) Survey EuroQol-visual analogue scales records the self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. 8 weeks
Primary Change from baseline (before using) to week 8 (after 6 weeks of using) of Insomnia severity index (ISI) Insomnia severity index has seven questions. Total score ranges from 0 to 28, where higher scores indicate more acute symptoms of insomnia. 8 weeks
Secondary Change from week 1 (before using) to week 8 (after 6 weeks of using) of Sleep efficiency (SE) Sleep efficiency is calculated as percentage of Total sleep time/time in bed. 8 weeks
Secondary Change from week 1 (before using) to week 8 (after 6 weeks of using) of Sleep quality (SQ) Sleep quality ranges from 1 to 5, where higher score indicates better quality of sleep. 8 weeks
Secondary Change from week 1 (before using) to week 8 (after 6 weeks of using) of Sleep onset latency (SOL) Sleep onset latency is evaluated as the time it takes a person to fall asleep after going to bed. 8 weeks
Secondary Change from week 1 (before using) to week 8 (after 6 weeks of using) of Wake after sleep onset (WASO) Wake after sleep onset is calculated as the total number of minutes that a person is awake after initially falling asleep. 8 weeks
Secondary Change from week 1 (before using) to week 8 (after 6 weeks of using) of Total sleep time (TST) Total sleep time is calculated as the total number of minutes that a person actually sleep. 8 weeks
Secondary Change from week 1 (before using) to week 8 (after 6 weeks of using) of Number of awakening (NOA) Number of awakening is evaluated as the number of times a person wakes up after falling asleep. 8 weeks
Secondary Change from baseline (before using) to week 8 (after 6 weeks of using) of Pittsburgh sleep quality index (PSQI) Pittsburgh sleep quality index has ten questions. Total score ranges from 0 to 21, where higher scores indicate lower quality of sleep. 8 weeks
Secondary Change from baseline (before using) to week 8 (after 6 weeks of using) of Dysfunctional beliefs and attitudes about sleep-16 (DBAS-16) Dysfunctional beliefs and attitudes about sleep-16 has sixteen questions. Responses can range from 0 to 10, where higher scores indicate more irrational belief and attitude toward sleep. 8 weeks
Secondary Change from baseline (before using) to week 8 (after 6 weeks of using) of Patient health questionnaire-9 (PHQ-9) Patient health questionnaire-9 has nine questions. Total score ranges from 0 to 27, where higher scores indicate more acute symptoms of depression. 8 weeks
Secondary Change from baseline (before using) to week 8 (after 6 weeks of using) of Generalized anxiety disorder-7 item scale (GAD-7) Generalized anxiety disorder-7 item scale has seven questions. Total score ranges from 0 to 21, where higher scores indicate more acute symptoms of anxiety. 8 weeks
Secondary Change from baseline (before using) to week 8 (after 6 weeks of using) of Epworth sleepiness scale (ESS) Epworth sleepiness scale has eight questions. Total score ranges from 0 to 24. A total score of 10 or less is evaluated as normal. A total score of 11 to 15 is evaluated as significant sleepiness. A total score of 16 or more is evaluated as pathological sleepiness. 8 weeks
Secondary Change from baseline (before using) to week 14 (after 6 weeks from close out visit) of Insomnia severity index (ISI) for WELT-IP group Insomnia severity index has seven questions. Total score ranges from 0 to 28, where higher scores indicate more acute symptoms of insomnia. 14 weeks
Secondary Percentage of subjects achieving SE = 85% 8 weeks
Secondary Compliance (completion rate of lessons, for WELT-IP group only) Compliance is evaluated as completion rate of lessons. 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT05963542 - Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia N/A
Completed NCT06339853 - Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia N/A
Recruiting NCT04069247 - Effectiveness of eCBT-I on Improving Mental Health in Chinese Youths With Insomnia N/A
Completed NCT04493593 - Internet-delivered CBT-I (Space for Sleep): Pilot and Feasibility N/A
Recruiting NCT06278077 - Neurexan - a Clinical Trial in Short-Term Insomnia Patients Phase 2
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT04661306 - The Better Sleep for Supporters With Insomnia Study N/A
Recruiting NCT06207279 - Preliminary Study on the Development and Reliability and Validity of Attention Rating Scale
Recruiting NCT06006299 - Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC) N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT04035200 - Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation Phase 2
Active, not recruiting NCT05027438 - Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention N/A
Recruiting NCT06053840 - An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients With Severe Insomnia Phase 4
Not yet recruiting NCT06348082 - Project Women's Insomnia Sleep Health Equity Study (WISHES) N/A
Not yet recruiting NCT06363799 - Osteopathic Protocol for Insomnia in College Students N/A
Not yet recruiting NCT06025968 - Digital Cognitive-behavioral Therapy for Insomnia for Patients With Multiple Sclerosis N/A
Not yet recruiting NCT05991492 - Improving Sleep With a Digital Cognitive Behavioral Therapy for Insomnia Application N/A